These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 19948506)

  • 1. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial.
    Kowey PR; Dorian P; Mitchell LB; Pratt CM; Roy D; Schwartz PJ; Sadowski J; Sobczyk D; Bochenek A; Toft E;
    Circ Arrhythm Electrophysiol; 2009 Dec; 2(6):652-9. PubMed ID: 19948506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trial.
    Beatch GN; Mangal B
    BMC Cardiovasc Disord; 2016 May; 16():113. PubMed ID: 27233239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation.
    Pratt CM; Roy D; Torp-Pedersen C; Wyse DG; Toft E; Juul-Moller S; Retyk E; Drenning DH;
    Am J Cardiol; 2010 Nov; 106(9):1277-83. PubMed ID: 21029824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of vernakalant in patients with atrial flutter: a randomized, double-blind, placebo-controlled trial.
    Camm AJ; Toft E; Torp-Pedersen C; Vijayaraman P; Juul-Moller S; Ip J; Beatch GN; Dickinson G; Wyse DG;
    Europace; 2012 Jun; 14(6):804-9. PubMed ID: 22291438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetic-pharmacodynamic analysis of vernakalant hydrochloride injection (RSD1235) in atrial fibrillation or atrial flutter.
    Mao Z; Wheeler JJ; Townsend R; Gao Y; Kshirsagar S; Keirns JJ
    J Pharmacokinet Pharmacodyn; 2011 Oct; 38(5):541-62. PubMed ID: 21786177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial.
    Roy D; Pratt CM; Torp-Pedersen C; Wyse DG; Toft E; Juul-Moller S; Nielsen T; Rasmussen SL; Stiell IG; Coutu B; Ip JH; Pritchett EL; Camm AJ;
    Circulation; 2008 Mar; 117(12):1518-25. PubMed ID: 18332267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vernakalant: conversion of atrial fibrillation in patients with ischemic heart disease.
    Torp-Pedersen C; Camm AJ; Butterfield NN; Dickinson G; Beatch GN
    Int J Cardiol; 2013 Jun; 166(1):147-51. PubMed ID: 22108512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm.
    Stiell IG; Roos JS; Kavanagh KM; Dickinson G
    Am Heart J; 2010 Jun; 159(6):1095-101. PubMed ID: 20569725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vernakalant hydrochloride: A novel atrial-selective agent for the cardioversion of recent-onset atrial fibrillation in the emergency department.
    Stiell IG; Dickinson G; Butterfield NN; Clement CM; Perry JJ; Vaillancourt C; Calder LA
    Acad Emerg Med; 2010 Nov; 17(11):1175-82. PubMed ID: 21175515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion.
    Torp-Pedersen C; Raev DH; Dickinson G; Butterfield NN; Mangal B; Beatch GN
    Circ Arrhythm Electrophysiol; 2011 Oct; 4(5):637-43. PubMed ID: 21841207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation.
    Camm AJ; Capucci A; Hohnloser SH; Torp-Pedersen C; Van Gelder IC; Mangal B; Beatch G;
    J Am Coll Cardiol; 2011 Jan; 57(3):313-21. PubMed ID: 21232669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update.
    Tsuji Y; Dobrev D
    Vasc Health Risk Manag; 2013; 9():165-75. PubMed ID: 23637539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous vernakalant: a review of its use in the management of recent-onset atrial fibrillation.
    Duggan ST; Scott LJ
    Drugs; 2011 Jan; 71(2):237-52. PubMed ID: 21275448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single oral dose of vanoxerine for the conversion of subjects with recent onset atrial fibrillation or flutter to normal sinus rhythm: RESTORE SR.
    Piccini JP; Pritchett EL; Davison BA; Cotter G; Wiener LE; Koch G; Feld G; Waldo A; van Gelder IC; Camm AJ; Kowey PR; Iwashita J; Dittrich HC
    Heart Rhythm; 2016 Sep; 13(9):1777-83. PubMed ID: 27108936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Vernakalant for Cardioversion of Recent-onset Atrial Fibrillation in the Asia-Pacific Region: A Phase 3 Randomized Controlled Trial.
    Beatch GN; Bhirangi K; Juul-Moller S; Rustige J
    J Cardiovasc Pharmacol; 2017 Feb; 69(2):86-92. PubMed ID: 27828791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vernakalant: RSD 1235, RSD-1235, RSD1235.
    Drugs R D; 2007; 8(4):259-65. PubMed ID: 17596113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines.
    Savelieva I; Graydon R; Camm AJ
    Europace; 2014 Feb; 16(2):162-73. PubMed ID: 24108230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vernakalant for Rapid Cardioversion of Recent-Onset Atrial Fibrillation: Results from the SPECTRUM Study.
    Lévy S; Hartikainen J; Ritz B; Juhlin T; Carbajosa-Dalmau J; Domanovits H
    Cardiovasc Drugs Ther; 2021 Apr; 35(2):283-292. PubMed ID: 33206300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic Review and Meta-analysis Appraising Efficacy and Safety of Vernakalant for Cardioversion of Recent-Onset Atrial Fibrillation.
    Ma W; Guo X; Wang Q; Sun G; Wang J
    J Cardiovasc Pharmacol; 2020 Jul; 76(1):32-41. PubMed ID: 32251022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group.
    Nørgaard BL; Wachtell K; Christensen PD; Madsen B; Johansen JB; Christiansen EH; Graff O; Simonsen EH
    Am Heart J; 1999 Jun; 137(6):1062-9. PubMed ID: 10347332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.